A site where you can find recommended contractors for non-clinical testing|effical " Non-Clinical CROs and Agencies " Clino Corporation

Clino Corporation

Table of Contents
Table of Contents

Clino Corporation collaborates with laboratory animal manufacturers to support non-clinical testing and evaluations using laboratory mini-pigs. This page will walk you through some of the key features of Clino Corporation’s non-clinical study capability, examples of disease models, and related case studies. It serves as a useful guide for selecting a CRO for non-clinical studies.

Non-Clinical Studies Conducted by Clino Corporation

Support for Large Animal Non-Clinical Studies

Clino Corporation specializes in non-clinical studies using large animals that enable testing under conditions similar to humans. In pharmaceutical and medical device development, large-animal testing plays an essential role in evaluating human-like reactions and device performance, which cannot be replicated in small animals such as rats or mice. While large-animal testing typically requires dedicated facilities, expert knowledge, and significantly higher cost, Clino Corporation overcomes these challenges through its nationwide coordination network, comprehensive animal management, and the supply of Micro Minipigs®. These capabilities ensure high-quality and reliable non-clinical studies.

Integrated Coordination and Animal Care Services

Leveraging its extensive domestic network, Clino Corporation provides comprehensive support in both study coordination and animal welfare before, during, and after the testing. This comprehensive one-stop service structure enables efficient and high-quality study execution while minimizing administrative tasks.

Provision of Unique Resources such as Micro Minipig®

Clino Corporation supplies the Micro Minipig®, one of the world’s smallest breeds of laboratory pigs developed in Japan. By utilizing this unique resource, the company offers non-clinical studies that closely mimic human physiology, earning strong recognition in the pharmaceutical and medical device sectors.

Partner CRO Introduced by Clino Corporation

Fuji Micra Co., Ltd.

Fuji Micra has independently developed ultra-small experimental pigs that weigh under 10 kg and measure less than 80 cm in length at six months of age—small enough to be housed in standard dog cages. Other disease models including atherosclerosis and chronic renal failure Micro Minipigs are available.

Case Studies

No case studies are currently listed on the official website.

Corporate Information

Clino originated as part of the research team within the Tohoku University Advanced Biomedical Engineering Research Organization, established in 2003 under the Ministry of Education, Culture, Sports, Science and Technology (MEXT) “Super COE” program (completed in 2008).

Address Collaboration Building, Aobayama Office, Research Center for Accelerator and Radioisotope Science (RARiS), Tohoku University, 6-3 Aoba, Aramaki Aza, Aoba-ku, Sendai, Miyagi, Japan
Tel 050-3716-5633
Website https://www.clino.org/
3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation
SMC Laboratories, Inc.
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)
  • SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
  • From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.

  • With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.
Safety Studies
Comprehensive Safety Evaluation for FIH Applications
Labcorp Holdings Inc.
(Labcorp Drug Development)
Labcorp Holdings Inc.
Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)
  • Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
  • The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
  • Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.
Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd.
Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)
  • PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
  • With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.

  • The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

By region
list of animal models
Expertise & Track Record
3 Recommended Contract Non-Clinical Testing Services